3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Pain, Intractable
1
Neoplasms
1
Neoplasm, Residual
1
Nausea
1
Leukemia, Myeloid, Acute
1
Dyspnea
1
Delirium
1
Death
1
Interventions
siremadlin
1
selinexor
1
posaconazole
1
midostaurin
1
fludarabine
1
durvalumab
1
blinatumomab
1
avelumab
1
Radiosurgery
1
Midazolam
1
Lenalidomide
1
Idarubicin
1
Dexamethasone
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium Dobesilate
1
Azacitidine
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasm, Residual
×
Midazolam
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn